Previous 10 | Next 10 |
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 30, 2021 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the appointment of Dr. Malte Gr...
The huge success of the mRNA vaccination platform during the pandemic has set a lot of people to thinking about what comes next. So mRNA-based techniques have a lot of power and a lot of promise. But there’s definitely a low-hanging-fruit area here, and that’s infect...
When most of a company's eggs are in one basket, it's entirely reasonable to want to sell your shares if you find out there's a big hole in the bottom. Such is the case with CureVac (NASDAQ: CVAC) in light of its most recent coronavirus vaccine trial. The latest data readout fro...
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 25, 2021 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the voting results of the Compan...
Matthias Hangst/Getty Images News CureVac ([[CVAC]] -5.1%) announced two membership changes at the company’s Supervisory Board. Ingmar Hoerr, former founding-CEO CureVac has withdrawn his candidacy for nomination to the Supervisory Board due to health reasons, the company said. Hoerr w...
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 23, 2021 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that Dr. Ingmar Hoerr, former Fo...
In the business world, one company's pain can mean another company's gain. You can double that with recent developments in the COVID-19 vaccine market. AstraZeneca (NASDAQ: AZN) has stumbled quite a bit in recent months with its COVID-19 vaccine program. There was a new developm...
CVAC tumbled in the double-digit percentage range after reporting disappointing efficacy pursuant to its COVID-19 vaccine. CVAC could attempt to launch a second-generation vaccine in collaboration with GSK next year. By the time a second-generation vaccine arrives, the COVID-19 ma...
The Federal Reserve is not tapering and will never predict a recession, even if they know one is imminent. Currently, the markets are focusing on the wrong things. This will self correct at some point. Inflation pressure is mounting but whether it will last or not will not be...
On June 17, shares of CureVac (NASDAQ: CVAC) plunged by over 50% during the trading session after the company announced its mRNA coronavirus vaccine candidate CVnCoV had achieved just 47% overall efficacy in preventing COVID-19 during the second interim analysis of a pivotal phase...
News, Short Squeeze, Breakout and More Instantly...
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context of the German patent ...
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone pa...
Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation to create leaner and more agile organization Prioritization of high-value opportunities in oncology and other selected diseases, leveraging proprietary mRNA tec...